Combined 177Lu-FAP-2286 Therapy and Chemotherapy in Extraskeletal Ewing Sarcoma With Multiple Metastases.

Clin Nucl MedSep 8, 2026 (epub)
Case ReportOncology (Medical)

Lixian Mou, Zhihan Yao, Wenlu Zheng et al.

✦ AI-curated · Sources linked

Case in brief

A 23-year-old male with metastatic extraskeletal Ewing sarcoma, who could not tolerate standard chemotherapy, was treated with 177Lu-FAP-2286 followed by reduced-dose chemotherapy. After two months, imaging revealed a significant metabolic response, including decreased tumor size and tracer uptake, with no reported adverse events. The patient remained symptom-free at this follow-up.

Diagnostic / clinical pearl

This case highlights the potential of 177Lu-FAP-2286 in combination with reduced-dose chemotherapy for patients with advanced Ewing sarcoma who are intolerant to standard treatments.

Source

PubMed · PMID 42710080

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.